Stephanie Noviello | CMO
ILIAD Biotechnologies

Stephanie Noviello, CMO, ILIAD Biotechnologies

Stephanie Noviello, M.D., M.P.H., Chief Medical Officer. Stephanie worked previously at Novartis as Senior Global Program Clinical Lead for assets in Immunology and skeletal Ddseases, submitting for multiple indications, creating clinical development plans for various assets and running a trial in COVID-19 patients. Stephanie also previously served as VP of Clinical Development at Motif BioSciences, developing an antibiotic for multidrug-resistant skin infections. She also spent over 6 years at Bristol-Myers Squibb, where she was the Virology Clinical Program Lead for the hepatitis B, hepatitis C and HIV portfolios. While at Bristol-Myers Squibb, she helped gain approval for the direct acting antivirals, daclatasvir and asunaprevir, for chronic hepatitis C. She previously worked at Schering-Plough Research Institute for 5 years running both adult and pediatric clinical trials evaluating the efficacy and safety of PegIntron and Rebetol for hepatitis C. Prior to working in industry she was an Epidemic Intelligence Service Officer at the Centers for Disease Control and Prevention stationed with the New York State Department of Health Bureau of Communicable Disease Control. She is a board-certified pediatrician with a Masters of Public Health and Tropical Medicine.


Day 2 - November 29 @ 16:30

BPZE1, an intranasal live attenuated pertussis vaccine, evaluated in a bordetella pertussis challenge study in healthy adults: a phase 2b, randomized, placebo-controlled study

last published: 02/Jan/24 12:15 GMT

back to speakers